Is Alx Oncology Stock a Good Investment?
Alx Oncology Investment Advice | ALXO |
- Examine Alx Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Alx Oncology's leadership team and their track record. Good management can help Alx Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Alx Oncology's business and its evolving consumer preferences.
- Compare Alx Oncology's performance and market position to its competitors. Analyze how Alx Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Alx Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Alx Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Alx Oncology Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Alx Oncology Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Alx Oncology Stock
Researching Alx Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alx Oncology Holdings recorded a loss per share of 2.97. The entity had not issued any dividends in recent years.
To determine if Alx Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alx Oncology's research are outlined below:
| Alx Oncology had very high historical volatility over the last 90 days | |
| Alx Oncology may become a speculative penny stock | |
| Alx Oncology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (160.81 M) with profit before overhead, payroll, taxes, and interest of 107 K. | |
| Alx Oncology Holdings currently holds about 313.37 M in cash with (130.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Alx Oncology has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Jaume Pons of 50000 shares of Alx Oncology at 1.65 subject to Rule 16b-3 |
Alx Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Alx Oncology Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alx Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Alx Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Alx Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-17 | 2021-03-31 | -0.41 | -0.35 | 0.06 | 14 | ||
2022-02-28 | 2021-12-31 | -0.62 | -0.7 | -0.08 | 12 | ||
2024-03-07 | 2023-12-31 | -0.84 | -0.93 | -0.09 | 10 | ||
2022-11-08 | 2022-09-30 | -0.77 | -0.87 | -0.1 | 12 | ||
2022-05-09 | 2022-03-31 | -0.71 | -0.6 | 0.11 | 15 | ||
2024-05-09 | 2024-03-31 | -0.84 | -0.71 | 0.13 | 15 | ||
2021-11-11 | 2021-09-30 | -0.48 | -0.61 | -0.13 | 27 | ||
2021-03-18 | 2020-12-31 | -0.35 | -0.48 | -0.13 | 37 |
Know Alx Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alx Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alx Oncology Holdings backward and forwards among themselves. Alx Oncology's institutional investor refers to the entity that pools money to purchase Alx Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 660.1 K | Privium Fund Management B.v. | 2024-09-30 | 509.1 K | Two Sigma Advisers, Llc | 2024-09-30 | 500.5 K | Qube Research & Technologies | 2024-09-30 | 457.7 K | Cubist Systematic Strategies, Llc | 2024-09-30 | 383.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 320.8 K | Northern Trust Corp | 2024-09-30 | 319.7 K | Xtx Topco Ltd | 2024-09-30 | 317.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 290.4 K | Venbio Partners Llc | 2024-09-30 | 9.7 M | Fmr Inc | 2024-09-30 | 5.9 M |
Alx Oncology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.83 M.Market Cap |
|
Alx Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.63) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.60) | (0.63) | |
| Return On Equity | (0.97) | (0.93) |
Determining Alx Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Alx Oncology is a good buy. For example, gross profit margin measures Alx Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alx Oncology's profitability and make more informed investment decisions.
Evaluate Alx Oncology's management efficiency
Alx Oncology Holdings has return on total asset (ROA) of (0.4925) % which means that it has lost $0.4925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9894) %, meaning that it created substantial loss on money invested by shareholders. Alx Oncology's management efficiency ratios could be used to measure how well Alx Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to drop to -0.63. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Alx Oncology's Non Current Assets Total are very stable compared to the past year. As of the 31st of January 2025, Total Current Assets is likely to grow to about 234.8 M, while Total Assets are likely to drop about 254.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.97 | 3.25 | |
| Tangible Book Value Per Share | 3.97 | 3.25 | |
| Enterprise Value Over EBITDA | (3.61) | (3.79) | |
| Price Book Value Ratio | 3.04 | 3.19 | |
| Enterprise Value Multiple | (3.61) | (3.79) | |
| Price Fair Value | 3.04 | 3.19 | |
| Enterprise Value | 730.1 M | 1.2 B |
The management strategies employed by Alx Oncology's are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.036 |
Basic technical analysis of Alx Stock
As of the 31st of January, Alx Oncology shows the Mean Deviation of 5.04, downside deviation of 6.53, and Risk Adjusted Performance of 0.0164. Alx Oncology Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Alx Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alx Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alx Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alx Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alx Oncology's Outstanding Corporate Bonds
Alx Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alx Oncology Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alx bonds can be classified according to their maturity, which is the date when Alx Oncology Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AMC ENTMT INC Corp BondUS00165AAH14 | View | |
| AMC Networks 425 Corp BondUS00164VAF04 | View | |
| AMC Entertainment Holdings Corp BondUS00165CBA18 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAB00 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAD65 | View | |
| AMC ENTMT HLDGS Corp BondUS00165CAP95 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Alx Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Alx Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0164 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 5.04 | |||
| Semi Deviation | 6.23 | |||
| Downside Deviation | 6.53 | |||
| Coefficient Of Variation | 10940.95 | |||
| Standard Deviation | 6.81 | |||
| Variance | 46.32 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0886 | |||
| Total Risk Alpha | (0.68) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 35.8 | |||
| Value At Risk | (9.46) | |||
| Potential Upside | 15.43 | |||
| Downside Variance | 42.62 | |||
| Semi Variance | 38.8 | |||
| Expected Short fall | (5.42) | |||
| Skewness | 0.331 | |||
| Kurtosis | 0.9035 |
| Risk Adjusted Performance | 0.0164 | |||
| Market Risk Adjusted Performance | (0.12) | |||
| Mean Deviation | 5.04 | |||
| Semi Deviation | 6.23 | |||
| Downside Deviation | 6.53 | |||
| Coefficient Of Variation | 10940.95 | |||
| Standard Deviation | 6.81 | |||
| Variance | 46.32 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0886 | |||
| Total Risk Alpha | (0.68) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | (0.13) | |||
| Maximum Drawdown | 35.8 | |||
| Value At Risk | (9.46) | |||
| Potential Upside | 15.43 | |||
| Downside Variance | 42.62 | |||
| Semi Variance | 38.8 | |||
| Expected Short fall | (5.42) | |||
| Skewness | 0.331 | |||
| Kurtosis | 0.9035 |
Consider Alx Oncology's intraday indicators
Alx Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alx Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 219458.0 | |||
| Daily Balance Of Power | (0.83) | |||
| Rate Of Daily Change | 0.9 | |||
| Day Median Price | 1.39 | |||
| Day Typical Price | 1.36 | |||
| Price Action Indicator | (0.15) | |||
| Period Momentum Indicator | (0.15) |
Alx Stock media impact
Far too much social signal, news, headlines, and media speculation about Alx Oncology that are available to investors today. That information is available publicly through Alx media outlets and privately through word of mouth or via Alx internal channels. However, regardless of the origin, that massive amount of Alx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alx Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alx Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alx Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alx Oncology alpha.
Alx Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Alx Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alx Oncology Corporate Management
| Lisa Sauer | Senior Assurance | Profile | |
| Peter MBA | Chief Officer | Profile | |
| Christopher JD | General Counsel | Profile | |
| Shelly CPA | Interim Officer | Profile | |
| Corey Goodman | Independent Chairman | Profile | |
| Shelly Pinto | Senior Officer | Profile | |
| Caitlyn Doherty | Manager Communications | Profile |
Already Invested in Alx Oncology Holdings?
The danger of trading Alx Oncology Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alx Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alx Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alx Oncology Holdings is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alx Oncology Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alx Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alx Oncology Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alx Oncology Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Alx Oncology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.